Objective. The location and mechanisms involved in the initial generation of autoantibodies to citrullinated and noncitrullinated proteins/peptides during the natural history of rheumatoid arthritis (RA) development is incompletely understood. This study sought to explore individual antibody responses to citrullinated and noncitrullinated proteins/peptides in the sputum and associations with neutrophil extracellular traps (NETs) in subjects at risk for the future development of RA.
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Objective. The location and mechanisms involved in the initial generation of autoantibodies to citrullinated and noncitrullinated proteins/peptides during the natural history of rheumatoid arthritis (RA) development is incompletely understood. This study sought to explore individual antibody responses to citrullinated and noncitrullinated proteins/peptides in the sputum and associations with neutrophil extracellular traps (NETs) in subjects at risk for the future development of RA.
Methods. Serum and sputum samples were obtained from 41 RA-free subjects who were considered at risk for the development of RA based on familial or serologic risk factors, from 20 subjects classified as having RA, and from 22 healthy control subjects. Samples were evaluated using a bead-based array for IgG reactivity to 29 citrullinated proteins/peptides and 21 noncitrullinated proteins/peptides. Cutoff levels for antibody positivity were established in a separate control group. NET levels in the sputum were measured using sandwich enzyme-linked immunosorbent assays that quantitate DNA-myeloperoxidase and DNA-neutrophil elastase complexes.
Results. In at-risk subjects, antibody responses to the citrullinated forms of fibrinogen, apolipoprotein E, and fibronectin were highly prevalent. The most citrulline-specific antibodies in the sputum of at-risk subjects were those to fibrinogen, vimentin, and peptides of fibrinogen A and apolipoprotein A1. Patterns of sputum autoantibody positivity differed between at-risk subjects and subjects with RA. In at-risk subjects, increasing sputum NET levels significantly correlated with several citrullinated and some noncitrullinated antibody reactivities.
Conclusion. These findings suggest that sputum antibody reactivity to particular citrullinated and noncitrullinated proteins/peptides is specific for RA and for subjects at risk of RA, and the association of these proteins/peptides with NETs may be a key feature of early RA-related autoimmunity in the lung. These results further support the hypothesis that the lung plays a role in early RA-related autoimmunity.
Citrullination is the posttranslational modification of peptidylarginine to peptidylcitrulline that is catalyzed through peptidylarginine deiminase (PAD) enzymes (1) . Citrullination is a normal physiologic process that can be up-regulated during inflammation (2) .
In addition, citrullination of certain self antigens has been associated with autoimmune responses that are characterized by antibodies to citrullinated protein/peptide antigens (ACPAs) (3) .
Serum ACPAs are strongly associated with rheumatoid arthritis (RA). In RA, ACPA reactivity to a number of different citrullinated protein/peptide antigens has been identified. Antibody reactivity to the native noncitrullinated counterparts of these antigens has also been identified in many RA patients (4) (5) (6) (7) (8) (9) . Furthermore, serum antibody reactivity to citrullinated and noncitrullinated antigens has been identified prior to the onset of clinically apparent synovitis during a "preclinical" phase of RA development (10) (11) (12) , and several studies have demonstrated that an increasing number of citrullinated antigens are targeted as individuals transition from a state of preclinical RA to classified RA (13, 14) . These findings suggest that a key part of RA development is early reactivity to a limited number of citrullinated as well as noncitrullinated antigens, with expansion/epitope spreading over time as inflammatory arthritis and classified RA develop.
As the goals in RA management shift to include the prevention of arthritis (15) , it is necessary to further understand the mechanisms underlying the initial development of antibody responses in RA and identify relevant immune targets for prevention. Several lines of evidence suggest that one major site where RA-related antibodies may be initially generated is the lung mucosa (16) (17) (18) (19) . Relevant to this study, our group has demonstrated through induced sputum testing that ACPAs, as characterized by anti-cyclic citrullinated peptide (anti-CCP) antibodies, are generated in the lung in a portion of subjects with classified RA and individuals with an increased risk of developing RA in the future (17, 19) . However, individual sputum antibody reactivities to citrullinated and noncitrullinated peptides/proteins have not been characterized in these subjects.
In addition to understanding early autoantibody targets in sputum, it is also important to understand potential mechanisms that could generate these autoantibody responses. One mechanism of particular interest is the formation of neutrophil extracellular traps (NETs). NET formation (termed NETosis) can externalize citrullinated and noncitrullinated proteins that can be taken up by antigen-presenting cells, which could lead to antibody generation (8) . NETs can also serve as antigenic targets for RA-related autoantibodies (20, 21) . Furthermore, our group has identified a strong positive correlation between sputum levels of anti-CCP and NETs in subjects at risk for RA (19) , but the individual sputum autoantibodies associated with NETosis have not been previously identified. Therefore, in this study, we sought to explore antibody responses to individual citrullinated and noncitrullinated proteins/peptides as well as associations with NETosis in the sputum of subjects at risk for the development of RA.
SUBJECTS AND METHODS
Study subjects. Recruitment. Subjects were recruited from the Studies of the Etiology of RA (SERA) Lung Study, as described in detail elsewhere (17, 19) . Briefly, the SERA Lung Study was designed to evaluate the natural history of RA through the prospective study of individuals who have an increased risk of developing RA in the future (22) . The SERA Lung Study was designed to study biomarkers of autoimmunity in the lung during different phases of RA development, using blood and sputum samples obtained from subjects in the SERA cohort who were considered at risk for RA, as well as subjects classified as having RA and healthy control subjects. For the current study, randomly selected stored samples from subjects who participated in the SERA Lung Study between January 2011 and December 2014 were included.
At-risk subjects. We included 41 subjects without current or prior inflammatory arthritis who were at risk for developing RA based on familial or serologic risk factors. Specifically, we included 30 subjects with a familial risk of RA, defined as having a first-degree relative (FDR) with RA. Four (13%) of 30 FDRs were serum anti-CCP positive (by the anti-CCP-2 and/or anti-CCP-3.1 tests). We also included 11 subjects with a serologic risk of RA, defined as having serum anti-CCP positivity (by the anti-CCP-2 and/or anti-CCP-3.1 tests) in the absence of inflammatory arthritis, as identified through community health fair, clinic, or research-based blood test screenings.
RA subjects. We included 20 subjects with established RA who met classification criteria for RA (23, 24) based on medical chart review. All were serum anti-CCP positive (by the anti-CCP-2 and/or anti-CCP-3.1 tests), and 16 (80%) of 20 were currently or previously taking disease-modifying antirheumatic drugs or biologic agents.
Healthy controls. We included 44 healthy control subjects who were recruited through local advertisement and were without RA or inflammatory arthritis, did not have an FDR with RA, and were serum anti-CCP negative (according to the anti-CCP-2 and anti-CCP-3.1 tests). These 44 subjects were randomly split into 2 groups of 22 each. One group was used to establish cutoff levels for antibody positivity (cutoff controls), and the other group was used for comparative analyses (comparator controls).
Study visit. Paired samples of blood and sputum were collected from all subjects at their study visit. Subjects without RA underwent a joint-focused interview and 66-count joint examination to confirm the absence of clinically evident inflammatory arthritis. Standardized questionnaires were used to obtain demographic information and self-reported histories of smoking and chronic lung disease.
Genetic testing. Blood was tested for the presence of alleles containing the shared epitope (SE), using previously described methods (22) . The alleles considered to contain the SE were as follows: DRB1*04:01, 04:04, 04:05, 04:08, 04:09, and 04:10, and DR1*01:01 and 01:02.
Sputum collection and processing. Induced sputum was collected using established protocols (17, 19) . Briefly, subjects underwent a 15-minute inhalation of nebulized hypertonic saline. To minimize salivary contamination, subjects underwent an oral wash prior to inhalation of saline, and during the sputum collection, subjects were instructed to spit any saliva into a separate container and only use the sputum collection cup when producing a sample from coughing. In addition, sputum samples used in this study had <10 squamous epithelial cells/ high-power field as revealed by light microscopy, or <80% squamous epithelial cells on cell differential testing, consistent with the lower airway origin of the sample (25, 26) .
After collection, the sputum sample underwent weightbased dilution with phosphate buffered saline, followed by mechanical syringe-based homogenization. Samples then underwent centrifugation, and the sputum supernatant was used for all biomarker testing.
Citrullinated and noncitrullinated antibody testing. Serum and sputum were tested for IgG reactivity to 29 individual citrullinated proteins/peptides using a bead-based array (developed in the laboratory of WHR), as described in detail elsewhere (3, 9, 27) . These citrullinated proteins/peptides were selected based on antigens that have been reported in the literature as well as those that have been identified in immune complexes isolated from the synovial tissue of RA patients (28) peptides, a noncitrullinated/native equivalent was also tested. Antigens were conjugated to spectrally distinct beads (Bio-Plex) and incubated with the subject's sample for 30 minutes at room temperature. After washing, the beads were incubated with phycoerythrin-conjugated anti-human IgG antibody at room temperature, and then passed through a Luminex 200 detector (Bio-Plex software version 5.0; Bio-Rad) that quantified (in fluorescence intensity) the amount of antibody bound to each bead. All antibody testing was performed in a blinded manner. We established a positive cutoff level in the sputum and serum for each citrullinated and noncitrullinated protein/ peptide antibody whose levels were above the 95th percentile of the 22 cutoff controls (i.e., present in <5%). This definition for autoantibody positivity is recommended in the American College of Rheumatology RA classification criteria (24) .
To test the reproducibility of the antigen array for sputum, 10 sputum samples were randomly selected, in a blinded manner, to undergo repeated testing for levels of antibodies to citrullinated antigens, and included samples from subjects with RA, at-risk subjects, and healthy control subjects. The mean AE SD coefficient of variation, which was calculated for each of the 29 antibodies to citrullinated antigens, was 7.2 AE 1.7%.
Anti-CCP testing. Clinical ACPA testing commonly uses commercially available anti-CCP assays, although these assays cannot distinguish individual ACPAs. In this study, serum was tested for anti-CCP using 2 different commercial enzyme-linked immunosorbent assays (ELISAs), the anti-CCP-3.1 ELISA (specific for IgG/IgA; Inova Diagnostics) and the anti-CCP-2 ELISA (specific for IgG; Axis-Shield). Serum positivity was determined on the basis of the manufacturer's recommended cutoff levels (≥20 units for anti-CCP-3.1 and >5 units for anti-CCP-2).
Sputum was also tested for anti-CCP, but this was limited to the anti-CCP-2 assay (targeting IgG). Because the anti-CCP-2 test is an IgG-only assay, it was comparable with the isotype reactivity detected by our antigen array testing. Results of the anti-CCP-2 test, expressed in ELISA units, were calculated using the standard curve provided by the manufacturer, followed by multiplication of the sputum dilution factor. We established a cutoff level for sputum anti-CCP-2 positivity using the same approach used for determining positive/negative levels of serum and sputum citrullinated and noncitrullinated antibodies (i.e., above the 95th percentile of the cutoff controls).
Rheumatoid factor (RF) testing. Sputum was tested for RF isotypes (IgA, IgG, and IgM) using commercial ELISAs (Inova Diagnostics). In accordance with the approach applied to other sputum antibody levels, we established a cutoff level for sputum RF positivity that was above the 95th percentile of the cutoff control group.
NET complex testing. Twenty-four at-risk subjects and 33 healthy controls who had an adequate volume of sputum available underwent NET testing. NETs were quantified in the sputum cell-free supernatant by measuring NET-specific protein/nucleic acid complexes, using a sandwich ELISA that detects DNA-myeloperoxidase (MPO) and DNA-neutrophil elastase (NE) complexes, as previously described (29) . Briefly, for DNA-MPO complexes, high-binding 96-well ELISA microplates were incubated overnight at 4°C with mouse anti-human MPO (clone 4A4; AbD, Serotec) in coating buffer from the Cell Death Detection ELISA kit (Roche). After blocking with 1% bovine serum albumin, plates were incubated overnight at 4°C with 10% sputum in blocking buffer and then washed, and anti-DNA-POD (monoclonal anti-DNA antibody from mouse clone MCA-33 conjugated with peroxidase; Roche) was added for 1.5 hours at room temperature. Tetramethylbenzidine substrate (Sigma) was then added, and the absorbance at 450 nm was measured after the addition of Stop reagent (Sigma). Because this assay detects binding of protein complexes and not antibodies, amplification of RF is unlikely.
Similar methods were used for the detection of DNA-NE complexes, with the antibody used to coat plates being rabbit anti-NE (Calbiochem). In addition, after overnight incubation with sputum, plates were incubated for 1 hour at room temperature with mouse anti-double-stranded DNA monoclonal antibody (Millipore), followed by anti-mouse IgGhorseradish peroxidase conjugate (Bio-Rad). To control for plate-to-plate variation, the same healthy control samples were included on every plate, and an optical density (OD) index was calculated based on the average absorbance at 450 nm in the healthy control samples. All samples were run in duplicate.
Statistical analysis. Characteristics of the subjects were compared between groups using the Kruskal-Wallis test for comparisons of age groups, and the chi-square/Fisher's exact test for comparisons of dichotomous variables. Regression models were used to compare associations between sputum antibody positivity (logistic models) and sputum antibody levels (linear models) while accounting for covariates. The median number of positive antibodies in the serum and sputum were compared using nonparametric matched-pairs analyses. Cohen's kappa coefficient was used to compare agreement between sputum and serum antibody positivity. Because antibody levels followed a nonnormal distribution, the Kruskal-Wallis test (for comparisons of 3 groups) and Mann-Whitney test (for comparisons of 2 groups) were used to compare antibody levels between groups, and Spearman's corelation coefficient was used to determine correlations between antibody and NET levels. Before comparing the different antibodies and because each antibody had a unique range of reactivity, we normalized the values for each antibody by dividing the antibody level by the median level in the cutoff control group for that particular antibody. In addition, when 518 DEMORUELLE ET AL comparing ratios of citrullinated antibody levels to noncitrullinated antibody levels, we used these normalized values. P values less than 0.05 were considered significant, except in analyses that compared each of the 29 individual antibodies. For these analyses, we used Bonferroni correction to account for multiple comparisons, and P values less than or equal to 0.002 (0.05 divided by 29 comparisons) were considered significant. All analyses were performed using SPSS software (version 23), and graphs were generated using GraphPad Prism (version 7).
RESULTS
Demographic characteristics. Compared to healthy controls, at-risk subjects and subjects with RA were older and marginally more often male. Furthermore, subjects with RA were more likely to be current smokers (Table 1) . Other demographic characteristics were not significantly different between the groups.
Sputum antibody responses to citrullinated proteins/peptides. Overall, sputum from 18 (43.9%) of 41 at-risk subjects and 15 (75.0%) of 20 RA subjects demonstrated ≥1 positive antibody response to 1 of the 29 citrullinated proteins/peptides tested (Table 1 ). This prevalence was significantly higher in at-risk subjects and RA subjects compared to healthy controls (each P < 0.01). In logistic regression analyses adjusted for age, at-risk and RA subjects were more likely to have ≥1 positive finding of sputum antibodies to a citrullinated protein/peptide compared to healthy controls (in at-risk subjects, odds ratio [OR] 21.3, 95% confidence interval [95% CI] 1.8-253.1; in RA subjects, OR 79.1, 95% CI 5.5-1,143.3). In addition, the total number of sputum antibodies to citrullinated proteins/ peptides was significantly higher in at-risk subjects and RA subjects compared to healthy controls (see Supplementary  Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40401/ abstract).
Within the group of at-risk subjects, the most prevalent sputum antibody responses to citrullinated proteins/ peptides were directed to Cit-fibrinogen (34.1%), Citapolipoprotein E (31.7%), Cit-fibronectin (31.7%), Cithistone 2B (29.3%), and Cit-histone 2A (26.8%) ( Table 2; for the full list, see Supplementary Table 2 [http://online library.wiley.com/doi/10.1002/art.40401/abstract]). In models accounting for multiple comparisons, anti-Cit-fibrinogen, anti-Cit-apolipoprotein E, and anti-Cit-fibronectin were significantly more prevalent in at-risk subjects compared to healthy controls (P ≤ 0.002).
Among subjects with RA, the most prevalent sputum antibodies to citrillunated proteins/peptides were directed to Cit-histone 2B (40.0%), Cit-filaggrin Table 2 and  Supplementary Table 2) . Sputum antibodies to Cit-histone 2B and Cit-filaggrin 48-65 cyclic were significantly more prevalent in RA subjects compared to healthy controls (P ≤ 0.002). Notably, antibodies to Cit-histone 2B and Cithistone 2A were among the most prevalent sputum antibody responses both in at-risk subjects and in RA subjects.
Sputum antibody responses to noncitrullinated proteins/peptides. In addition to anticitrullinated antibodies, antibodies to noncitrullinated/native proteins * In comparisons of rheumatoid arthritis (RA)-free at-risk subjects who were included based on familial risk factors versus those included based on serologic risk factors, there was no significant difference in any of the characteristics listed, except that the frequency of serum anti-cyclic citrullinated peptide (anti-CCP) positivity was higher in serologic at-risk subjects compared to familial at-risk subjects (100% versus 13%; P < 0.01). Notably, there was no difference in the prevalence of ≥1 sputum anti-citrullinated protein antibody (ACPA)-positive result in at-risk subjects stratified by inclusion risk factor (47% of familial at-risk subjects versus 36% of serologic at-risk subjects; P = 0.73).
† P values for comparison of median age between all groups were determined by Kruskal-Wallis test. P values for comparisons of prevalence of or positivity for any of the other characteristics between all groups were determined by chi-square/Fisher's exact test. ‡ Only 18 of the 20 RA subjects had DNA available for shared epitope testing. § Positivity for ACPAs was defined as a positive antibody response to 1 of the 29 citrullinated proteins/peptides tested in this study.
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have been identified in the serum of subjects with preclinical or early classified RA (4-9). These findings suggest that early autoimmunity may be characterized by reactivity to native proteins initially, with evolution to citrullinated epitopes over time through epitope spreading. Therefore, it is important to understand antibody reactivity to both citrullinated and noncitrullinated antigens during different phases of RA development. Overall, we identified ≥1 positive finding for a sputum antibody to a noncitrullinated protein/peptide in 23 (56.1%) of 41 at-risk subjects and 13 (65.0%) of 20 RA subjects. Frequency of sputum positivity for ≥1 antibody to a noncitrullinated antigen was significantly higher both in at-risk subjects and in RA subjects compared to healthy controls (56% and 65%, respectively, versus 14% in healthy controls; each P < 0.01).
Comparison of sputum antibody responses to citrullinated and noncitrullinated proteins/peptides. For the 21 antibodies that had a citrullinated and noncitrullinated antigen counterpart, we examined the subjects who demonstrated sputum antibody positivity to citrullinated proteins/peptides and considered a citrullinated:noncitrullinated ratio of >1 to be consistent with specificity for citrullinated antigens. In at-risk subjects with a positive test result for a sputum antibody to any citrullinated protein/peptide, a high prevalence of citrulline-specific antibodies (in ≥75% of subjects) was demonstrated for the proteins fibrinogen and vimentin and the peptides apolipoprotein A1 [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] , fibrinogen A 556-575 cyclic , and fibrinogen A 582-599 (Table 3 ). In RA subjects with a positive test result for a sputum antibody to any citrullinated protein/peptide, a high prevalence of citrulline-specific antibodies (in ≥75% of subjects) was demonstrated for the proteins histone 2A, histone 2B, and vimentin and the peptides histone . In RA subjects compared to at-risk subjects, there was a nonsignificant trend toward a higher prevalence of citrulline specificity for fibrinogen A 616-635 cyclic and filaggrin 48-65 cyclic . In addition, in the * Values are the number of at-risk subjects or rheumatoid arthritis (RA) subjects with a citrullinated:noncitrullinated ratio of >1/total number of subjects with a positive sputum antibody response to that particular protein or peptide (percentage). All citrullinated:noncitrullinated ratios were calculated as the normalized antibody level divided by the median level for that antibody in the cutoff control group. None of the P values for between-group differences (calculated by Fisher's exact test) were significant. 520 DEMORUELLE ET AL 1 comparator control subject who had positive findings for sputum antibodies to 2 citrullinated proteins/peptides, both antibody responses demonstrated citrulline specificity with a citrullinated:noncitrullinated ratio of >1.
Comparison of sputum ACPA positivity by antigen array and by anti-CCP-2 ELISA. We found that in all 6 at-risk subjects who were sputum anti-CCP-2 positive and in 11 (92%) of 12 RA subjects who were sputum anti-CCP-2 positive, a positive test result for ≥1 sputum antibody to a citrullinated protein/peptide was also demonstrated on the antigen array. All of these sputum anti-CCP-2-positive at-risk and RA subjects with a positive antibody response to a citrullinated protein/peptide demonstrated citrulline specificity to at least one of those antigens based on a citrullinated:noncitrullinated ratio of >1. In 12 (34%) of the 35 at-risk subjects and 4 (50%) of the 8 RA subjects who were sputum anti-CCP-2 negative, a positive result for ≥1 sputum antibody to a citrullinated protein/peptide was demonstrated on antigen array. Among the 12 anti-CCP-2-negative at-risk subjects and 4 anti-CCP-2-negative RA subjects who had a positive antibody response to a citrullinated protein/peptide, 11 at-risk subjects and all 4 RA subjects demonstrated citrulline specificity to at least one of those antigens.
Sputum antibody positivity in subjects stratified by serum antibody status. In assays of the same 29 citrullinated proteins/peptides that were tested in the sputum, we identified 18 (44%) of 41 at-risk subjects and 19 (95%) of 20 RA subjects who had ≥1 positive finding of an antibody to a citrullinated antigen in the serum. The majority of these serum antibody responses demonstrated citrulline specificity (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.40401/abstract). Additionally, in at-risk subjects, antibodies to the proteins fibrinogen and vimentin as well as the peptides fibrinogen A 582-599 and fibrinogen A 556-575 cyclic demonstrated high citrulline specificity both in the sputum and in the serum.
Following these experiments, we stratified at-risk subjects based on serum positivity for antibodies to citrullinated antigens. The rationale for this stratification is that more of the at-risk subjects who had already developed a systemic RA-related autoimmune response could be assumed to be further along the pathway to developing classifiable RA compared to serum antibody-negative individuals, although even among serum ACPA-positive subjects, not all will develop classifiable RA. In these analyses, we tested for reactivity to the 29 citrullinated protein/peptide antigens and found ≥1 positive finding for a sputum antibody in 6 (33.3%) of 18 serum antibodynegative at-risk subjects and 12 (52.2%) of 23 serum antibody-positive at-risk subjects. The prevalence of each sputum anticitrullinated antibody stratified by serum status is listed in Supplementary Within the group of at-risk subjects, there was overall poor agreement with regard to findings of a positive antibody response to citrullinated antigens between the sputum and the serum (j ≤ 0.25). However, there was higher agreement for Cit-enolase 1A [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] (j = 0.55), for which 4 (50%) of 8 at-risk subjects who were positive for anti-Cit-enolase 1A [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] in the sputum also showed positivity in the serum.
Among the at-risk subjects who were negative for serum antibodies to citrullinated antigens, the most Figure 1 . Sputum levels of antibodies to citrullinated proteins by subject group. Levels of sputum anti-Cit-fibrinogen (A), anti-Cit-apolipoprotein E (B), and anti-Cit-fibronectin (C) were compared between comparator healthy controls (HC) (n = 22), serum anti-citrullinated protein antibody (ACPA)-negative at-risk (AR) subjects (n = 18), serum ACPA-positive at-risk subjects (n = 23), and rheumatoid arthritis (RA) subjects (n = 20). An antibody response to a citrullinated protein/peptide antigen was defined as antibody positivity to any of the 29 citrullinated antigens tested in the study. Symbols represent individual subjects; horizontal lines indicate the median. * = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001, by MannWhitney U test. prevalent sputum antibodies were directed to Cit-fibrinogen (27.8%), Cit-apolipoprotein E (22.2%), and Citfibronectin (22.2%). Similarly, among at-risk subjects who were positive for any serum antibody response to a citrullinated protein/peptide, the most prevalent sputum antibodies were to Cit-fibrinogen (39.1%), Cit-apolipoprotein E (39.1%), and Cit-fibronectin (39.1%), but also included Cit-histone 2B (39.1%), Cit-histone 2A (34.8%), Cit-enolase 1A 5-21 (30.4%), Cit-apolipoprotein E 277-296 cyclic (30.4%), and Cit-vimentin (30.4%). These rates were all higher compared to the rates in healthy controls (each P ≤ 0.05), with a significantly higher prevalence of antibodies to Cit-fibrinogen, Citapolipoprotein E, Cit-fibronectin, and Cit-histone 2B (each P ≤ 0.002).
In addition to the prevalence of antibody positivity, the median levels of anti-Cit-fibrinogen, anti-Citapolipoprotein E, and anti-Cit-fibronectin in the sputum were each significantly higher in serum antibody-positive at-risk and RA subjects compared to healthy controls ( Figures 1A-C) .
Sputum NET levels and ACPA positivity in at-risk subjects. Overall, sputum NET levels were higher in atrisk subjects with ≥1 positive antibody response to a citrullinated or noncitrullinated antigen in the sputum (n = 15) compared to sputum antibody-negative healthy controls (n = 27). Specifically, in at-risk subjects with ≥1 positive antibody response to a citrullinated or noncitrullinated antigen, the median OD index for sputum DNA-MPO was 6.3 (interquartile range [IQR] 3.7-8.1) as compared to 3.7 (IQR 3.1-4.4) in healthy controls (P < 0.01), and for DNA-NE, the median OD index was 4.9 (IQR 2.6-12.2) as compared to 3.5 (IQR 2.6-5.0) in healthy controls (P = 0.06). These differences are consistent with our prior published findings with regard to NET levels in sputum anti-CCP-positive at-risk subjects and healthy control subjects (19) .
We also determined correlations between the sputum levels of NET complexes and antibodies to citrullinated and noncitrullinated proteins/peptides, using a conservative approach that identified significant associations only if 2 separate NET assays (those for DNA-MPO and DNA-NE) demonstrated a significant correlation (P ≤ 0.002) after accounting for multiple comparisons. With this approach, we found a significant positive correlation between sputum NET levels and the majority of antibody responses to citrullinated proteins/peptides (27 [93%] of 29) in the sputum (Table 4 and Figures 2A-D) . Furthermore, after adjustment for a history of ever smoking-a factor that has been associated with NETosis (30,31)-sputum NET levels remained significantly associated with 15 of 29 antibodies, including antibodies to Cit-fibrinogen, Cit-apolipoprotein A1 [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] , and Cit-fibrinogen A 582-599 (Table 4) , all of which also had been demonstrated to have high sputum citrulline specificity in at-risk subjects. The following antigens also demonstrated significant associations between sputum NET levels and the antibody responses to the citrullinated antigen, but not the noncitrullinated antigen, after adjustment for ever smoking: histone 2A/a-2 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , fibrinogen A 211-230 cyclic , fibrinogen B [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] , and vimentin 58-77 cyclic .
Of note, a noncitrullinated form of the antigen was not available for testing of the following antigens that showed significant associations between sputum antibodies to citrullinated proteins/peptides and NET levels: apolipoprotein E, apolipoprotein E 277-296 cyclic , histone , and filaggrin 48-65 cyclic . † This citrullinated protein/peptide remained significantly correlated with DNA-MPO and DNA-NE levels (P ≤ 0.002) after adjustment for ever smoking.
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DEMORUELLE ET AL 2A/a-2 1-20 cyclic , and fibrinogen A [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Moreover, there was no significant difference in age, sex, race, frequency of SE positivity, or smoking history between the 24 atrisk subjects who underwent NET testing and the 17 who did not (data not shown).
We also examined the 33 healthy controls who underwent sputum NET testing. There was a significant correlation (P ≤ 0.002) between sputum NET levels and levels of antibodies to the following peptides: Cit-biglycan Correlations of sputum NET levels and RF levels. To determine whether the relationships seen between NET levels and citrullinated/noncitrullinated antibodies were limited to the antibodies discussed above or whether they might involve other autoantibody systems, we evaluated the correlation of sputum NET levels and sputum RF isotypes in the 9 at-risk subjects who were negative for sputum citrullinated and noncitrullinated antibodies. We found a significant correlation between IgA-RF and NET levels in the sputum, using both NET assays (for DNA-MPO, P < 0.01; for DNA-NE, P = 0.04). However, there was no significant association between NET levels and IgM-RF or IgG-RF (for IgM-RF, P = 0.24 on the DNA-MPO assay, P = 0.61 on the DNA-NE assay; for IgG-RF, P = 0.10 on the DNA-MPO assay, P = 0.27 on the DNA-NE assay). These results suggest that there is not a general association between autoantibodies and NETs in the sputum. Of interest, these findings are consistent with those in prior studies that demonstrated a strong association of Figure 2 . Correlations between sputum anti-citrullinated protein antibody (ACPA) levels and neutrophil extracellular trap (NET) levels in at-risk subjects. Sputum levels of anti-Cit-fibrinogen (A), anti-Cit-apolipoprotein E (B), anti-Cit-apolipoprotein A1 231-248 (C), and anti-Cit-histone 2B (D) in at-risk subjects were analyzed in relation to sputum levels of NETs, as measured with DNA-myeloperoxidase (MPO) complexes. Symbols represent individual subjects. Correlations were calculated using Spearman's correlation coefficients (r values). FI = fluorescence intensity.
IgA-RF with NET formation, whereas IgG-RF was weakly associated, and IgM-RF was not associated, with NET formation (32) .
DISCUSSION
Understanding the development of ACPAs is a critical step in understanding the overall etiology and pathogenesis of RA. Our prior work demonstrated the presence of anti-CCP antibodies in the sputum of subjects considered at risk for the development of RA (17, 19) . In this study, we demonstrate for the first time that a subset of individual antibody responses to citrullinated and noncitrullinated antigens are detectable in the sputum of subjects at risk for RA, including at-risk subjects who are serum antibody negative; these findings are thereby informative of very early RA-related autoantibody development. We also demonstrate that sputum antibodies to both citrullinated and noncitrullinated antigens are significantly more prevalent in at-risk subjects and RA subjects compared to healthy controls. Furthermore, several sputum antibodies were found to be strongly correlated with increasing NET levels in subjects at risk for RA. Taken together, these data suggest that sputum antibody responses to particular citrullinated and noncitrullinated antigens, in association with higher levels of local NETosis in the lung, may be a key feature of early RA-related autoimmunity.
In this study, we found several sputum antibodies of particular interest in subjects at risk for RA. Sputum anti-Cit-fibrinogen, anti-Cit-apolipoprotein E, and antiCit-fibronectin antibodies were more prevalent in at-risk subjects, including serum ACPA-negative at-risk subjects, suggesting that these proteins may represent the earliest antigen targets of antibodies generated in the lung in subjects at risk of RA. In particular, anti-Cit-fibrinogen demonstrated high citrulline specificity in the sputum and serum of at-risk subjects. In the lung, protein levels of fibrinogen, apolipoprotein E, and fibronectin are known to be increased in the setting of inflammation and injury (33) (34) (35) , and lung tissue plasma cells in RA patients have demonstrated production of anti-Cit-fibrinogen antibodies (36) . Linking these concepts and considering our prior work demonstrating increased inflammation of the airways in at-risk subjects (16, 19) , it may be that increased levels of these proteins promote the generation of an autoimmune response in a portion of subjects at risk of developing RA.
In addition to fibrinogen, antibodies directed to vimentin, fibrinogen A [582] [583] [584] [585] [586] [587] [588] [589] [590] [591] [592] [593] [594] [595] [596] [597] [598] [599] , and fibrinogen A 556-575 cyclic also demonstrated citrulline specificity in the sputum and serum of at-risk subjects. In addition, antibodies to Cit-enolase 1A [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] uniquely demonstrated agreement between the sputum and the serum in at-risk subjects. Although these findings are cross-sectional, they suggest that these antibody responses may play a role in transitions from localized mucosal to systemic autoimmunity. An additional sputum antibody of interest is antiCit-histone 2B, which was the only sputum antibody to a citrullinated antigen that was significantly more prevalent both in serum antibody-positive at-risk subjects and in serum antibody-positive RA subjects compared to healthy controls. Antibodies directed to Cit-histone 2B also demonstrated higher citrulline specificity in the sputum of RA subjects. Taken together with the findings from murine models demonstrating that NET-associated anti-Cithistone 2B antibodies were associated with development of arthritis (37) , these data suggest that anti-Cit-histone 2B in the sputum may be relevant in the transition from an at-risk status to classified RA.
We also found that the individual sputum antibodies most prevalent in at-risk subjects differed from those most prevalent in subjects with classified RA. While this finding could be related to the effects of RA treatment, it may also reflect epitope spreading or changes in the lung during the evolution of RA-related autoimmunity. Moreover, we found that the number of autoantigens demonstrating high citrulline specificity increased in the sputum from at-risk subjects to RA subjects, and increased to a larger degree in the serum. While epitope spreading is well described in the serum during the preclinical period of RA (13, 38) , our findings suggest that epitope spreading may also occur in the lung, although longitudinal studies are needed to test this hypothesis. Recently, our group described a significant correlation between sputum levels of anti-CCP and sputum levels of NET remnants (19) . In this study, we expanded on that finding to demonstrate that several sputum antibodies to citrullinated as well as noncitrullinated antigens significantly correlated with sputum NET levels in at-risk subjects. Sputum NETs correlated with antibodies to Cit-histone and Cit-vimentin peptides, but not their noncitrullinated counterparts, and it is of interest that these are 2 citrullinated proteins that have been identified in the protein cargo of NETs induced in the neutrophils of patients with RA (20) .
In this study, we could not determine whether immunogenic proteins on NETs triggered local autoantibody generation or whether local autoantibodies triggered the increase in NET levels. However, findings from several recent studies support the hypothesis that NETs could trigger ACPAs, including studies showing that NETs themselves may trigger immune responses associated with autoimmunity (39) , that NETs in lupus patients can alter the structure and function of proteins, including 524 DEMORUELLE ET AL apolipoproteins (40) , and that the uptake of NET proteins by antigen-presenting cells is associated with systemic ACPAs (8) .
We also identified correlations between sputum NETs and antibodies to citrullinated antigen targets that have not been previously described in NETs. Additional studies are needed, but this finding could be attributed to a unique protein cargo in the NETs generated in atrisk subjects, the release of PAD enzymes from NETs, which can result in citrullination of nearby proteins that could trigger ACPAs (41) or can result in cross-reactivity of ACPAs to several citrullinated antigen targets, as has been demonstrated in RA patients (42) (43) (44) . It is of note that whereas some ACPAs in patients with RA demonstrate cross-reactivity to multiple citrullinated antigens, others demonstrate nonoverlapping citrullinated antigen binding (43) . We also found that multiple anti-citrullinated antigen antibodies and RF-IgA, but not RF-IgM and RF-IgG, were associated with markers of NETosis in the sputum, suggesting that NETs are preferentially associated with certain antibodies. Overall, these findings support the importance of additional studies that could specifically address the possibility of antibody cross-reactivity in the sputum as well as the role of NETs in specific antibody responses.
Furthermore, we identified correlations between sputum NETs and several sputum antibodies to citrullinated and noncitrullinated antigens in healthy controls. Although the sputum antibody levels were significantly lower in healthy controls compared to at-risk subjects or RA subjects, these findings suggest the possibility that even in individuals without a known risk for RA, low levels of antibody responses to citrullinated or noncitrullinated antigens may be associated with mucosal NETosis, perhaps reflecting a role for antibodies to citrullinated or noncitrullinated antigens in the normal regulation of mucosal processes that, in some cases, may become dysregulated, leading to greater mucosal immunity, and ultimately to systemic inflammation and classified RA. Each of these potential mechanisms and hypotheses could improve our understanding of the early phases of ACPA development and should be explored in future studies.
In this study, we also found that at-risk and RA subjects had higher sputum reactivity to noncitrullinated proteins/peptides compared to healthy controls. This finding suggests that broad antibody reactivity to both noncitrullinated and citrullinated antigens occurs in the lungs of these subjects, but that more citrulline-specific reactivity is generated toward certain antigens and is more prevalent in subjects with RA. These findings support the hypothesis that early localized autoimmunity may be directed to native proteins, with evolution to citrullinated epitopes occurring through epitope spreading (4) (5) (6) 45) . However, it is also possible that tolerance to citrullinated proteins is initially broken, and that the autoimmune responses to epitopes intramolecularly spread to native epitopes on the same proteins. Longitudinal studies are needed to understand the temporal relationship between antibodies to citrullinated and noncitrullinated proteins/peptides.
There are several caveats to our study, including its cross-sectional design, which limits inferences regarding the evolution of autoantibody responses over time. In addition, there is the potential for oral-pharyngeal contamination of the sputum, and antibody translocation from the circulation. However, we believe that the novel cross-sectional findings in this study are important to support longitudinal studies. In addition, as described in Subjects and Methods, since we ensured careful collection of the sputum samples to minimize salivary contamination, and since we previously demonstrated the minimal translocation of antibodies from the serum to the sputum (17, 19) , we believe that the findings herein reflect lung and airway biology. Furthermore, the antigen array that we used was based on proteins known to be relevant in the RA joint, and while there are shared RA-related antigens between the lung and joints (46) , it may be that to more deeply understand initial breaks in tolerance related to the lung, the autoimmune response to lungspecific antigens needs to be evaluated. Furthermore, the portion of our at-risk population who were sputum ACPA positive is likely higher than the portion who will go on to develop classified RA. Longitudinal studies will be informative to understand what factors lead to progression from local mucosal to systemic autoimmunity and, ultimately, classified RA.
We also did not test for antibody cross-reactivity in this study. While future studies are needed in this area, we believe our current findings cannot all be explained by cross-reactivity, because some individuals had only 1 positive finding of a sputum antibody to a single citrullinated antigen, and some individuals had sputum antibodies to citrullinated antigens in the absence of positivity for a noncitrullinated antibody. Finally, serum ACPA fine specificities differ between different RA populations (47) , and it may be that similar findings could occur in the sputum, supporting the importance of additional sputum studies in other at-risk populations.
In conclusion, we identified several sputum autoantibodies of particular interest in subjects at risk for the future development of RA, including sputum ACPAs with early citrulline specificity and those with strong associations with NETs in the sputum. These findings further support the hypothesis that the lung likely plays an important role in the development and evolution of RArelated autoimmunity.
